/

Empresas

Ga

No verificado

Gan & Lee Pharmaceuticals

Sobre qué escribimos

FarmacéuticaFitnessMedicina - VariosSaludSanidad

12 Comunicados de prensa

Ver todos los comunicados de prensa

Press Release cover image

12/06/2026

Salud

Fitness

Medicina - Varios

Gan & Lee Pharmaceuticals Achieves Significant Progress in Its Dual Pipeline for Metabolic Diseases -- Weekly Insulin Ludefen (GZR4) Meets Primary Endpoint in Phase III Clinical Trial in China; Bofanglutide Meets Primary Endpoints in Phase III Weight Loss Study in China and Phase II Study in the U.S.

Fuente

Gan & Lee Pharmaceuticals

Editor

1.00

0

Press Release cover image

09/04/2026

Salud

Fitness

Mercado laboral

Legislación/Derecho

Fiscalidad/Impuestos

Medicina - Varios

Gan & Lee Pharmaceuticals Signs Exclusive License Agreement with JW Pharmaceutical, the Leading South Korean Pharma, to Advance the Global Commercialization of the Innovative GLP-1 Receptor Agonist Bofanglutide

Fuente

Gan & Lee Pharmaceuticals

Editor

1.00

0

Press Release cover image

31/03/2026

Salud

Fitness

Medicina - Varios

Gan & Lee Pharmaceuticals' Once-Weekly Basal Insulin GZR4 Injection Meets Primary Endpoints in Two Pivotal Phase 3 Clinical Trials: SUPER-1 and SUPER-2

Fuente

Gan & Lee Pharmaceuticals

Editor

1.00

0

10/03/2025

Farmacéutica

Sanidad

Economía

Start-up

Gan & Lee Pharmaceuticals Announced First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide (GZR18) Injection for Overweight or Obesity

Fuente

Gan & Lee Pharmaceuticals

Editor

1.00

0

Press Release cover image

18/12/2024

Farmacéutica

Banca

Sanidad

Ciencia

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial)

Fuente

Gan & Lee Pharmaceuticals

Editor

1.00

0

Press Release cover image

12/11/2024

Farmacéutica

Sanidad

Gan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks

Fuente

Gan & Lee Pharmaceuticals

Editor

1.00

0

Press Release cover image

11/11/2024

Farmacéutica

Sanidad

ObesityWeek®️ 2024 | Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical Data for GZR18 Injection in Chinese Overweight and Obese Adults

Fuente

Gan & Lee Pharmaceuticals

Editor

1.00

0

Press Release cover image

15/10/2024

Farmacéutica

Sanidad

Gan & Lee Pharmaceuticals' Three Innovative Drugs: GZR18 Injection, GZR4 Injection, and GZR101 Injection Achieve Primary Endpoints in Phase 2 Clinical Studies

Fuente

Gan & Lee Pharmaceuticals

Editor

1.00

0

Press Release cover image

14/09/2024

Farmacéutica

Sanidad

Biología

Gan & Lee Pharmaceuticals Presented Two Positive Clinical Results of Once-weekly Insulin GZR4 at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD 2024)

Fuente

Gan & Lee Pharmaceuticals

Editor

1.00

0

Press Release cover image

22/07/2024

Farmacéutica

Sanidad

Biología

Gan & Lee Pharmaceuticals' Bi-weekly (twice a month) GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial

Fuente

Gan & Lee Pharmaceuticals

Editor

1.00

0

Seguidores

0

Compatibilidad

0